Michael Gelband’s Protagonist Therapeutics PTGX Stock Holding History

Michael Gelband’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-124,929	Closed	-$8.3M	–	1960
2025 Q3	$8.3M	Buy	+124,929	New	+$7.1M	0.08%	241
2025 Q1	–	Sell	-29,870	Closed	-$1.15M	–	1898
2024 Q4	$1.15M	Buy	+29,870	New	+$1.3M	0.01%	901
2023 Q4	–	Sell	-177,125	Closed	-$2.95M	–	1942
2023 Q3	$2.95M	Buy	177,125 +162,471	+1,109%	+$3.15M	0.03%	542
2023 Q2	$405K	Buy	+14,654	New	+$367K	﹤0.01%	1427
2023 Q1	–	Sell	-90,107	Closed	-$983K	–	2059
2022 Q4	$983K	Sell	90,107 -18,769	-17%	-$158K	0.01%	952
2022 Q3	$918K	Sell	108,876 -2,250	-2%	-$21.3K	0.01%	1145
2022 Q2	$879K	Buy	+111,126	New	+$1.34M	0.01%	1143
2021 Q1	–	Sell	-15,701	Closed	-$317K	–	2506
2020 Q4	$317K	Buy	+15,701	New	+$338K	﹤0.01%	1519
2019 Q2	–	Sell	-30,119	Closed	-$379K	–	1286
2019 Q1	$379K	Buy	30,119 +15,919	+112%	+$141K	0.03%	403
2018 Q4	$96K	Buy	+14,200	New	+$113K	0.01%	312

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Michael Gelband's PTGX Position: Q4 2025 in Review

Michael Gelband sold out of Protagonist Therapeutics (PTGX) in Q4 2025, closing a stake of 124,929 shares — an estimated $8.3M sold.

Michael Gelband first reported a position in PTGX in Q4 2018 and held it in 10 quarters. The position peaked at $8.3M in Q3 2025. 315 funds tracked by Wall St. Rank hold PTGX as of Q4 2025.

Michael Gelband reported no remaining Protagonist Therapeutics position as of Q4 2025 after selling out during the quarter.
Michael Gelband sold 124,929 Protagonist Therapeutics shares in Q4 2025, an estimated $8.3M.
Michael Gelband first reported a position in Protagonist Therapeutics in Q4 2018 and held it in 10 quarters.
Michael Gelband's Protagonist Therapeutics position peaked at $8.3M in Q3 2025.
315 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2025.

Based on ExodusPoint Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.